Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2401 participants.

Also called NCT04363697

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,401 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04363697
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04363697. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-24 (actual); primary completion 2025-06-02 (actual). Results posted on 2026-06-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
Condition
Acute Heart Failure
Condition
Heart Failure
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Placebo
Lead sponsor
The TIMI Study Group (class: other)
Collaborator
AstraZeneca (class: industry)
Collaborator
Worldwide Clinical Trials (class: other)

Record details

Record id
cardio:ct-nct04363697
Content hash
65fa3b4cdc25427e0803ed63e1f1a1e64ccbf4a36d1785215fb1776fe5746474